Paper Review Records
全部论文审稿周期
21 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
86
天
Vaccine profile of adjuvanted RSVPreF3 in adults: prevention of RSV-related lower respiratory tract disease and emerging evidence of potential cardiovascular and respiratory benefits
作者
Nancy Dezutter; Katherine Theiss-Nyland; Marie-Pierre David; Quentin Deraedt; Christian Felter; Maria João Fonseca; Susan I. Gerber; Emily K. Horn; Veronica Hulstrøm; Philip Joosten; Jean-Yves Pirçon; Bruno Salaun; Pei-Yong Shi; Marie Van der Wielen; Natalie Vassilouthis; Lucile Warter; Lisa White; Dominique Descamps; Susie Barnes; Sanjay Gurunathan展开收起
作者单位
1. GSK展开收起
163
天
Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials
作者
Kangning Wang; Jialei Hu; Huagen Chen; Zhu Wang; Xianchao Zhu; Hongxing Pan展开收起
作者单位
1. School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing, China; 2. Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing, China; 3. Jiangsu Provincial Medical Innovation Center, National Health Commission (NHC) Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing, China; 4. Shanghai Reinovax Biologics Co., Ltd., and Changchun Reinovax Biologics Co., Ltd., Shanghai, China展开收起
75
天
The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysis
作者
Matthew Napier; Angus Macfarlane; Ellie Tunnicliffe; Simon Brassel; Camilla Cahill; Sally Ryan; Christoph Lohan; Valda Struwig; Jeffrey Vietri; Diana Mendes; Tianyan Hu; Lotte Steuten展开收起
作者单位
1. Office of Health Economics; 2. Pfizer Australia Pty; 3. Pfizer展开收起
51
天
40
天
238
天
Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary
作者
Laura Wagner; Marc Messier; James H. Stark; Erik Lamberth展开收起
作者单位
1. aValneva Austria GmbH, Vienna, Austria; 2. bGlobal Vaccines and Anti-infectives Medical and Scientific Affairs, Pfizer Inc, Cambridge, MA, USA; 3. cVaccine Research and Development, Pfizer Inc, Collegeville, PA, USA展开收起
FAQ
Expert Review of Vaccines审稿要多久?
截至2026-11-19,CrushSCI 收录了 Expert Review of Vaccines 的 21 篇完整审稿记录。最快一篇从收稿到录用用了 25 天(Rational design of M2e-based nanoparticle vaccines for universal influenza a protection,2026-07-17 收稿,2026-08-11 录用),最慢一篇用了 322 天;平均 143.2 天,中位数 123 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
